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Abstract
Global loss of DNA methylation and locus/gene-specific gain of DNA methylation are two distinct hallmarks of
carcinogenesis. Aberrant DNA methylation is implicated in smoking-related lung cancer. In this study, we have
comprehensively investigated the modulation of DNA methylation consequent to chronic exposure to a prototype smoke-
derived carcinogen, benzo[a]pyrene diol epoxide (B[a]PDE), in genomic regions of significance in lung cancer, in normal
human cells. We have used a pulldown assay for enrichment of the CpG methylated fraction of cellular DNA combined with
microarray platforms, followed by extensive validation through conventional bisulfite-based analysis. Here, we demonstrate
strikingly similar patterns of DNA methylation in non-transformed B[a]PDE-treated cells vs control using high-throughput
microarray-based DNA methylation profiling confirmed by conventional bisulfite-based DNA methylation analysis. The
absence of aberrant DNA methylation in our model system within a timeframe that precedes cellular transformation
suggests that following carcinogen exposure, other as yet unknown factors (secondary to carcinogen treatment) may help
initiate global loss of DNA methylation and region-specific gain of DNA methylation, which can, in turn, contribute
to lung cancer development. Unveiling the initiating events that cause aberrant DNA methylation in lung cancer has
tremendous public health relevance, as it can help define future strategies for early detection and prevention of this highly
lethal disease.
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Introduction
Lung cancer is the chief cause of cancer-related mortalities,
worldwide [1,2]. The death toll of lung cancer is estimated to
reach 1.5 millions in 2010 [2]. The projection of the enormous
global burden of this malignancy in the 21
st century underscores
the significance of this disease as an ominous public health
problem. Etiologically, tobacco smoking continues to represent the
single most important risk factor for lung cancer development [2].
Although the initial flurry of research has unraveled many aspects
of smoke-derived lung carcinogenesis, the exact underlying
mechanism of this malignancy awaits further delineation [3,4].
The gaps in mechanistic knowledge of smoke-associated lung
cancer constitute the main obstacle in the management of this
disease, which is currently diagnosed mostly at late stages with
poor response to surgery, chemotherapy, and/or radiotherapy that
leads to high mortality [3]. Elucidation of the underlying
mechanism of smoke-induced lung carcinogenesis can help define
future strategies for early diagnosis, prognosis, treatment, and
prevention of lung cancer [4].
Epigenetic mechanisms of carcinogenesis manifest as heritable
changes in gene expression without involving alterations in the
underlying DNA sequence [5,6,7]. Aberrant DNA methylation is
the best-studied epigenetic mechanism, and causally implicated in
human cancer [5,6]. A global loss of DNA methylation
(hypomethylation) and a locus/gene-specific gain of DNA
methylation (hypermethylation) are two distinct hallmarks of
carcinogenesis [7,8]. Whereas DNA hypomethylation is thought
to contribute to oncogenesis by reactivation of latent retro-
transposons, induction of genomic instability, and activation of
protooncogenes [9,10], DNA hypermethylation is believed to
elicit tumorigenesis by transcriptional silencing of tumor sup-
pressor genes [5,6,7,8]. Aberrant DNA methylation occurs
predominantly in the context of 59-CpG-39 dinucleotides (CpGs)
[5,6,7,8]. In mammalian genomes, the vast majority of CpGs are
normally methylated, e.g., 80–90% of CpGs in the human
genome are methylated [5,6,7]. The remaining methylation-free
CpGs are found in stretches of .500 base pairs (bp) with a GC
content of .55% and an observed/expected CpG ratio of $0.65,
conventionally termed ‘‘CpG islands’’ [11]. Of significance is the
genomic locations of CpG islands, which often span the 59 end
region (promoter, untranslated region and exon 1) of many genes,
e.g., ,70% of all human promoters encompass CpG islands
[5,6,7]. Hypermethylation of CpG islands in the promoter
regions of tumor suppressor genes concomitant with their
transcriptional silencing have been observed in virtually all types
of human cancer, including various smoking-related malignancies
[5,6,7,8,12,13]. Global DNA hypomethylation has also been
found in a variety of human cancers, albeit with ambiguous link
to smoking per se [14,15,16,17].
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class of carcinogenic compounds present in tobacco smoke, as
well as in numerous other sources, including occupational,
environmental, e.g., dietary, and medicinal sources [18].
Benzo[a]pyrene (B[a]P) is a prototype PAH, which requires
metabolic activation to its ultimate carcinogenic form, B[a]P
diol epoxide (B[a]PDE), to exert its biological effects in vivo [18].
In the early 1980 s, a few epigenetic studies have used B[a]P
and/or B[a]PDE, as model tobacco-smoke carcinogens, to
investigate the modulation of DNA methylation in vitro
[19,20,21]. Modification of DNA with B[a]PDE resulted in
impairment of DNA methyltransferase (DNMT) activities,
manifested as inhibition of catalyzing reaction between the
methyl donor S-adenosylmethionine (SAM) and the substrate
DNA [19,20,21]. Furthermore, treatment of murine cell lines
C3H/10T1/2 and BALB/3T3 A31 with B[a]P caused a
reduction in the 5-methylcytosine content of cellular DNA,
albeit only in the latter cell line [19]. More recently, two other
studies have investigated the effects of these chemicals on DNA
methylation in MCF-7 breast cancer cells [22] and immortal-
ized bronchial epithelial cells [23]. Applying a restriction
enzyme-based, polymerase chain reaction (PCR) –dependent
microarray approach, non-conclusive and counterintuitive
results were obtained regarding the methylation status of a
subset of human CpG islands interrogated in the former study
[22]. Despite no alteration in mRNA expressions of the
maintenance DNMT1 or the de novo DNMT3a or DNMT3b,
there were increased levels of DNMT1 protein and promoter
hypermethylation of several genes of the panel of 30 genes
analyzed in the latter study [23]. Altogether, it would be
oversimplistic, however, to expect a direct link between DNA
methylation status and DNMTs, either at the expression or
activity level [24,25,26,27], considering the simultaneous
occurrence of global DNA hypomethylation and region-specific
DNA hypermethylation in cancer [5,6,7,24,25]. The modula-
tion of DNA methylation consequent to carcinogen exposure,
therefore, should be investigated by cataloguing DNA methyl-
a t i o np r o f i l e ,o nag e n o m e - w i d e scale or in genomic regions of
potential significance in cancer, preferably in ‘normal’ human
cells challenged with carcinogens. To date, the current literature
lacks a comprehensive study of such design, however.
We have recently developed a versatile DNA methylation
detection method, the methylated-CpG island recovery assay
(MIRA), in combination with microarray platforms [28], which
enables analysis of DNA methylation status in individual genes as
well as in large number of genes, genome-wide [12,13,29,30]. As a
pulldown assay for enrichment of the methylated CpG content of
cellular DNA, the MIRA is based on the ability of the methyl-CpG
binding (MBD) proteins, the MBD2b/MBD3L1 complex, to
specifically bind methylated-CpG dinucleotides [28,31]. The
MIRA-enriched DNA fraction, without undergoing restriction
enzyme digestion or PCR amplification, can be fluorescently
labeled and hybridized to commercially available CpG island/
genome tiling arrays [28]. In the present study, we have used a
MIRA-assisted microarray approach to establish DNA methyla-
tion profiles in normal human fibroblasts chronically exposed to
B[a]PDE in vitro. For verification purposes, we have scrutinized the
data obtained by our MIRA-assisted microarray analysis using the
conventional combined bisulfite-restriction analysis (COBRA)
[32], and the gold standard of DNA methylation analysis, sodium
bisulfite genomic sequencing [33]. Here, we have specifically
scanned chromosomal gene-rich regions of very frequent allele loss
in lung tumors [34], as well as long- and short interspersed nuclear
elements (LINE and SINE, respectively), and long terminal repeat
(LTR) retrotransposons, and segmental duplications whose
activation through hypomethylation relates to genomic instability
and lung cancer [13,35,36].
Results
Efficiency of carcinogen treatment
Using a well-defined validated cell culture model system and
under strictly controlled experimental conditions, we have
investigated the modulation of DNA methylation consequent to
chronic exposure to the smoke-derived activated carcinogen,
B[a]PDE. To fairly mimic a real life situation, we treated the cells
repeatedly with biologically effective doses of B[a]PDE on a daily
basis with 3-day-intervals in between the treatments. Of
significance, we ensured that the administered doses of B[a]PDE
did not severely affect the proliferative capacity of the cells because
the maintenance of DNA methylation pattern is dependent upon
DNA replication during cell division [5,6,7,8]. As shown in Figure
S2, we verified the efficiency of carcinogen treatment in our model
system by confirming the interaction of B[a]PDE with cellular
DNA in carcinogen-treated normal human fibroblasts. In all cases,
proliferatively-competent cell cultures treated with B[a]PDE did
reach nearly full confluency, and required multiple rounds of
passaging during the course of treatment.
High-throughput DNA methylation cataloging
Using NimbelGen tiling array (Roche NimbleGen, Inc.,
Madison, WI), we have established the status of DNA methylation
in chromosomes 7 and 8 in B[a]PDE-treated normal human
fibroblasts, applying the MIRA-assisted microarray approach. As
illustrated in Figure S1, we utilized three different hybridization
designs, including (I) MIRA-enriched B[a]PDE-treated DNA vs
MIRA-enriched DMSO-treated DNA, (II) MIRA-enriched
B[a]PDE-treated DNA vs Input non-enriched B[a]PDE-treated
DNA, and (III) MIRA-enriched DMSO-treated DNA vs Input
non-enriched DMSO-treated DNA. No PCR amplification was
performed on the MIRA-enriched fractions before hybridization
to the arrays. Applying very stringent bioinformatics criteria, we
made comparative analysis between DNA methylation patterns
found in various genomic regions in B[a]PDE-treated cells vs
control. Overall, we observed strikingly similar patterns of DNA
methylation in B[a]PDE-treated cells vs control. The remarkable
resemblance of DNA methylation status between B[a]PDE-treated
cells and control is shown at different representative genomic
regions in Figure 1 and Figure S3. Marginal differences in DNA
methylation patterns found at certain loci in B[a]PDE-treated cells
vs control were deemed non-significant after statistical analysis. On
average, the most pronounced fold-difference in the extent of
DNA methylation between B[a]PDE-treated cells and control, as
indicated by peaks, for example in Figure 1 and Figure S3, did not
exceed 1.66 for hypermethylated targets. No hypomethylated
targets, even at a fold-difference level of 1.50, was detectable in
B[a]PDE-treated cells vs control. For comparison, we have
previously established the profile of DNA methylation in smokers’
lung tumors vs adjacent non-tumorous tissues, as determined by
parallel analysis [13]. In the latter case, the fold-differences (tumor
vs normal lung) in the extent of DNA methylation reached more
than 10 for several hundred hypermethylated targets, and more
than 3 for several thousand hypomethylated targets [13]. Of note,
we have also repeated the above analysis using the promoter CpG
island microarrays (Agilent Technologies Inc.), which cover
virtually the entire set of CpG islands of the human genome.
Similarly to results obtained by the chromosomal tiling arrays, we
did not find any significant difference in the extent of CpG islands
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shown).
Furthermore, we performed an electromobility shift assay [28]
to determine the affinity of the MBD2b/MBD3L1 complex for
methylated CpGs in the presence and absence of B[a]PDE-DNA
adducts. The latter was to rule out the possibility that B[a]PDE-
DNA adduction at methylated CpGs may adversely affect the
formation of MBD2b/MBD3L1 complex at these dinucleotides,
thus, impeding the MIRA pulldown procedure. As shown in
Figure S4, we found invariable formation of the MBD2b/
MBD3L1 complex in a 55-mer methylated CpG containing-
oligonucleotide, in the presence and absence of B[a]PDE-DNA
adducts.
Conventional DNA methylation profiling
We validated the data obtained by MIRA-assisted microarray
analysis using the conventional COBRA assay [32] and bisulfite
genomic sequencing [33]. We randomly selected differentially, yet
marginally, methylated target loci/genes identified by the above
analysis in B[a]PDE-treated cells vs control, and established their
methylation status, individually. In agreement with our MIRA-
assisted microarray data, both the COBRA [32] and bisulfite
genomic sequencing [33] analyses showed no significant difference
in the profile of DNA methylation between B[a]PDE-treated cells
and control for all the analyzed targets. As shown in Figures 2–5,
there were remarkably similar patterns of DNA methylation in all
the examined targets in B[a]PDE-treated cells vs control.
To specifically determine DNA hypomethylation events conse-
quent to carcinogen treatment, we investigated the methylation
status of LINE, SINE, and LTR retrotransposons, and segmental
duplications in bisulfite-treated DNA from B[a]PDE-treated cells
vs control. We adapted a published procedure [37], which involves
primer amplification of the consensus sequences from the
respective elements followed by appropriate restriction enzyme
digestion or direct sequencing. Evolutionarily, methylated CpGs
on the forward- or reverse strands of these elements can undergo
spontaneous deamination of 5-methylcytosine to thymine, thereby
mutating to 59-TpG-39 or 59-CpA-39, respectively. Dependent on
the status of cytosine methylation, non-mutated CpGs can be
converted to 59-TpG-39 (if unmethylated) or remain unchanged (if
methylated) after bisulfite treatment of DNA in vitro (see, Fig. S5)
[37]. Whereas restriction enzyme digestion of bisulfite-treated and
PCR-amplified DNA can help differentiate between methylated
CpGs and unmethylated and/or mutated CpGs, direct genomic
sequencing will provide detailed information on the status of CpG
methylation and mutation in these elements [13,37]. As shown in
Figures 3 and 4, neither restriction enzyme digestion- nor direct
sequencing of bisulfite-treated and PCR-amplified fragments
derived from these elements showed any significant difference in
the extent of CpG methylation between B[a]PDE-treated cells and
control. For comparison, we have presented readily detectable
hypomethylation of these elements in A549 lung cancer cell line,
as determined by parallel analysis (see, Fig. 3).
Because lung cancer is derived from the epithelial compartment
of the lung, we also extended our DNA methylation analysis to
normal human bronchial epithelial cells (Cambrex, Walkersville,
MD) exposed repeatedly to B[a]PDE using the same treatment
protocol, which was used for normal human fibroblasts (see,
Material and Methods). As the former cell type was much more
sensitive to carcinogen assault, we could maximally treat these cells
with 0.2 mMB [ a]PDE for 6 consecutive daily doses with 3-day-
intervals in between the treatments. Similarly to results found in
normal human fibroblasts chronically exposed to B[a]PDE, we
observed no appreciable difference in the extent or profile of DNA
methylation between B[a]PDE-treated normal human bronchial
epithelial cells and control, as determined by our MIRA-based
microarray analysis followed by extensive validation through
conventional bisulfite-based analysis (data not shown).
Discussion
Aberrant DNA methylation is the most-extensively studied
epigenetic mechanism of carcinogenesis [5,6,7,8], and implicitly
involved in smoking-related lung cancer [3,12,13]. The underlying
involvement of aberrant DNA methylation in lung carcinogenesis,
in particular in tumor initiation, however, awaits further
elucidation [5,6,12,13]. In the present study, for the first time,
we have comprehensively investigated the modulation of DNA
methylation in normal human cells chronically exposed to a
typical smoke-derived carcinogen, B[a]PDE [18]. Using our
recently developed methylation detection method, the MIRA-
assisted microarray approach [28], together with conventional
COBRA [32] and bisulfite sequencing [33], we have scanned
genomic regions of relevance for lung cancer in normal human
cells treated with B[a]PDE in vitro.
We set up a treatment protocol that resembled - as much as
technically possible – a real life situation, in which normal human
cells were exposed chronically to biologically effective doses of
B[a]PDE, while allowing for the potential epigenetic effects to
occur in proliferatively-competent cells. Using our high-through-
put MIRA-assisted microarray analysis [28], we found remarkably
similar patterns of DNA methylation in B[a]PDE-treated cells vs
control. Methodologically, the MIRA enrichment procedure takes
advantage of the property of the MBD2b/MBD3L1 complex to
specifically bind methylated-CpGs [28,31]. Of all MBD proteins,
MBD2b has the highest affinity for methylated CpGs [38], and the
binding reaction is enhanced in the presence of the MBD3L1
protein [28,31]. As shown in Figure S4, we have empirically ruled
out the possibility that B[a]PDE-DNA adduction at methylated
CpGs may adversely affect the formation of MBD2b/MBD3L1
complex at these dinucleotides. Thus, we verified that MIRA-
based analysis is appropriate for studying DNA methylation in
B[a]PDE-treated cells herein.
Our MIRA-assisted microarray approach is a genome-scale
interrogation assay for detecting aberrant DNA methylation,
including global hypomethylation and locus/gene specific hyper-
methylation [12,13,28,29,31]. Despite being comprehensive, the
approach is very straightforward inasmuch as it does not rely on
commonly used procedures, such as restriction enzyme digestion
or PCR amplification of DNA, for detecting aberrant DNA
methylation. The latter two procedures are known to be impeded
by the presence of bulky adducts in lesion-bearing DNA
[39,40,41,42]. To further provide proof of evidence on the utility
Figure 1. Comparison of DNA methylation profiles between B[a]PDE-treated cells and control by MIRA-assisted microarray analysis.
Genomic DNA of normal human fibroblasts chronically treated with B[a]PDE vs DMSO was subjected to MIRA-assisted microarray analysis, as described
in the text. Representative methylation array profiles from different chromosomal regions are displayed with corresponding genomic coordinates
(indicated on the top). MIRA-T/MIRA-UT’ = MIRA-enriched B[a]PDE-treated DNA vs MIRA-enriched DMSO-treated DNA, ‘MIRA-T/Input’ = MIRA-enriched
B[a]PDE-treated DNA vs Input non-enriched B[a]PDE-treated DNA, and ‘MIRA-UT/Input’ = MIRA-enriched DMSO-treated DNA vs Input non-enriched
DMSO-treated DNA.
doi:10.1371/journal.pone.0010594.g001
DNA Methylation & Cancer
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methylation patterns in the genome, we also verified the validity of
the data obtained by our MIRA-assisted microarray analysis using
the well-established COBRA [32] and bisulfite sequencing
methods [33]. As shown in Figures 2–5, we confirmed the validity
of MIRA-assisted microarray data by demonstrating that there
was no significant difference in DNA methylation profile between
B[a]PDE-treated cells and control using conventional analysis of
the representative targets identified by the high throughput
MIRA-based analysis.
Our study is unique in that we have comprehensively
investigated the modulation of DNA methylation consequent to
exposure to a smoke-derived carcinogen, in genomic regions of
significance in lung cancer, in ‘normal’ human cells challenged
with relevant doses of carcinogen. Previous studies have implicated
a relationship between aberrant DNA methylation and smoking-
related lung cancer [14,15,16,17]. However, mechanistic studies
have yet to establish the exact nature of this relationship by finding
the sequence of events that lead to global loss of DNA methylation
and locus/gene-specific gain of DNA methylation, which may, in
turn, contribute to lung cancer development. It is conceivable that
carcinogen exposure can cause a variety of epigenetic effects, such
as histone-modifications and chromatin remodeling, microRNA-
derived modulation of gene-expression, etc. [6,7,43,44], which
may, secondarily and upon engagement of a parallel transforming
event, impact upon DNA methylation. Considering the known
genotoxic effects of carcinogens present in tobacco smoke [4], it is
also plausible that aberrant DNA methylation associated with lung
carcinogenesis [45,46,47], may as well be a secondary event that is
triggered by, e.g., mutations in crucial genes that can directly or
indirectly influence key pathways involved in DNA methylation. It
can be envisaged that carcinogen-induced epigenetic or genetic
alterations, which can affect the DNA methylation network, e.g.,b y
up- or down-regulating the expression or activities of DNMTs or
Figure 2. Locus/gene-specific verification of DNA methylation profiles in B[a]PDE-treated cells vs control by COBRA and bisulfite
genomic sequencing. Differentially, yet marginally, methylated target loci/genes identified by MIRA-assisted microarray analysis in B[a]PDE-treated
cells vs control, were selected randomly, and subjected to conventional COBRA [32] and bisulfite sequencing analyses [33] to establish their
methylation status, individually. The lack of ‘hypermethylation’ in the specified targets was confirmed by the COBRA [32] and/or genomic sequencing
[33] methods. For comparison, we have presented readily detectable hypermethylation of one of these targets (RASSF1A) in A549 lung cancer cell line.
Data from independent B[a]PDE-treated samples, indicated by superscript numbers, e.g.,B [ a]PDE
1, are shown. UT = DMSO-treated DNA; T = B[a]PDE-
treated DNA. (N) = Methylated CpG; (#) = Unmethylated CpG;
mCG: Absolute number of methylated CpGs/total CpGs (% methylated CpGs); None
of the differences in
mCG% between B[a]PDE-treated DNA vs control was statistically significant (Fisher’s exact test).
doi:10.1371/journal.pone.0010594.g002
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PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10594Figure 3. Locus/gene-specific verification of DNA methylation profiles in B[a]PDE-treated cells vs control by COBRA and bisulfite
genomic sequencing. The lack of ‘hypomethylation’ in the segmental duplications encompassing LINE and LTR retrotransposons was confirmed by
DNA Methylation & Cancer
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downstream regulatory genes, may initiate global DNA hypo-
methylation and/or region-specific DNA hypermethylation, which
can, in turn, give rise to lung tumorigenesis.
Previous studies by others have investigated indirectly and/or
non-comprehensively the modulation of DNA methylation
consequent to exposure to smoke-related carcinogens
[19,20,21,22,23]. Of concern in these studies are methodological
and/or conceptual issues, such as using excessive treatment
conditions, e.g., naked DNA treatment with high concentrations
of B[a]PDE [19,20,21], evaluating various proxies for inferring
DNA methylation status, e.g., DNMTs activities or expression
[19,20,21,23], or assaying cancerous [22] or immortalized cell
lines [23] for establishing DNA methylation patterns in a limited
number of genes. For example, in studies by Wilson and Jones
[19,20], in vitro modification of genomic DNA with extreme doses
of B[a]PDE resulted in 12 adducts per 10
3 nucleotides. Such
adduct levels of B[a]PDE are physiologically not attainable, e.g.,
leukocytes DNA from average smokers contains ,3B [ a]PDE-
DNA adducts per 10
8 nucleotides [48]. Also, indirect evaluation of
DNA methylation status based on proxy quantification cannot
provide definitive information as the relationship between such
indicators and DNA methylation is less than straightforward
[24,25,26,27]. Inherent in model systems that utilize cancerous or
immortalized cell lines are the unknowns regarding their
‘‘comparability’’ to normal human cells [49]. Additional concerns
include technical uncertainties surrounding the applied DNA
methylation detection systems. For instance, application of a
restriction enzyme-based, PCR–dependent microarray approach
for studying DNA methylation in B[a]PDE-treated cells has
proved unsuccessful [22] due to the potential interference of
B[a]PDE-DNA adducts with restriction enzyme digestion and/or
PCR-amplification steps involved therein [39,40,41,42].
Currently, high throughput next-generation sequencing projects
are analyzing large numbers of human lung tumors. These
projects are poised to identify unique pathways that are adversely
affected in human lung cancer. To infer causality, however, the
aberration of these pathways does need to be experimentally
recapitulated. For example, it is likely that next-generation
sequencing of human lung tumors will elucidate genetic or
epigenetic alterations that are specifically associated with exposure
to tobacco smoke carcinogens. The relevance of such findings
should be verified in validated experimental model systems under
well-defined and controlled exposure conditions. As the upcoming
data from the sequencing of smokers’ lung-cancer genomes and
epigenomes will become available, validated model systems should
help delineate various aspects of the pathogenesis of this disease.
Of importance, genetic or epigenetic mechanisms affecting specific
pathways should be investigated so that their role as a driving force
behind each individual pathway can be clearly established.
Lastly, we acknowledge that B[a]PDE-treatment of normal
human cells in the present study is a reasonable recapitulation of
chronic exposure to smoke-derived carcinogens, albeit much
shorter than what typical smokers’ lung cells experience in vivo.
Here, the resistance of normal human cells to undergo
transformation in vitro prevented us from examining the possibility
that aberrant DNA methylation may occur as a rare stochastic
event in individual cells, which might then be selected for through
a growth advantage [23]. Admittedly, we should also consider a
different scenario, in which smoke-derived carcinogens, other than
B[a]PDE, are the culprit epimutagens that may cause aberrant
DNA methylation in lung carcinogenesis.
In conclusion, we have demonstrated that in vitro chronic
treatment of normal human cells with a prototype smoke-derived
carcinogen, B[a]PDE [18], does not result in aberrant DNA
methylation in genomic regions of relevance for lung cancer,
within a timeframe that precedes cellular transformation. Our data
warrant further mechanistic research into the sequence of
epigenetic and/or genetic events, which initiate global loss of
DNA methylation and locus/gene-specific gain of DNA methyl-
ation that may, in turn, contribute to lung cancer development.
Identifying the initiating events that cause aberrant DNA
methylation in lung cancer has significant public health relevance,
as it can help define future strategies for early diagnosis and
prevention of this malignancy.
Materials and Methods
Ethics Statement
Having read the ‘‘PLoS ONE Guidelines for Authors’’, all the
authors of this manuscript confirm that, an ethics statement is not
required for this work.
Cell culture and chemical treatment
The normal human fibroblast cells used in the present study are
described in References [50,51]. Early passage normal human
fibroblasts, prepared from neonatal foreskin [50,51], were grown
as monolayer at ,25% confluence in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Irvine Scientific, Santa Ana, CA) supplement-
ed with 10% fetal bovine serum (FBS). Prior to chemical
treatment, the culture media were removed, and the cells were
washed thoroughly with phosphate buffered saline (PBS). The
culture dishes were filled with serum free DMEM, and
subsequently freshly prepared B[a]PDE (1 mM) (Midwest Research
Institute, Kansas City, MO) or control solvent [dimethylsulfoxide
(DMSO)] were added to the media, and incubation was performed
at 37uC for 20 minutes in the dark. Immediately after treatment,
the cells were washed with PBS, fed with complete growth
medium (DMEM plus 10% FBS), and cultivated for 3 days, after
which an ensuing round of chemical treatment was carried out, as
described above. When reaching approximately 90% confluency,
all cultures underwent passaging (1 to 3 split) either 24- or
48 hours post chemical treatment. Three days after the 10
th round
of B[a]PDE treatment, the cells were harvested by trypsinization,
and subjected to genomic DNA isolation using the DNeasy
purification kit (Qiagen, Valencia, CA). The above-specified
treatment protocol was based on our preliminary tests in which
we established that normal human fibroblasts well-tolerate
multiple rounds of treatment with 1 mMB [ a]PDE, while having
83–89% survival rate and preserving their proliferation capacity
by replicating once every 32–36 hours. All experiments were
conducted in triplicate.
Immuno-dot-blot assay
To verify the efficiency of B[a]PDE treatment in normal human
fibroblasts, we used a standard immuno-dot-blot assay [52], and
confirmed the interaction of this chemical with cellular DNA in
carcinogen-treated cells. The immuno-dot-blot assay utilizes the
the COBRA [32] and genomic sequencing [33] methods. For comparison, we have presented readily detectable hypomethylation of these repetitive
DNA elements in A549 lung cancer cell line. None of the differences in
mCG% between B[a]PDE-treated DNA vs control was statistically significant
(Fisher’s exact test). C = HeLa DNA methylated in vitro with M. SssI CpG methyltransferase. (See, also legend for Fig. 3).
doi:10.1371/journal.pone.0010594.g003
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PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10594Figure 4. Locus/gene-specific verification of DNA methylation profiles in B[a]PDE-treated cells vs control by COBRA and bisulfite
genomic sequencing. The lack of ‘hypomethylation’ in the SINE (ALU) and LINE retrotransposons was confirmed by the COBRA [32] and genomic
sequencing [33] methods; none of the differences in
mCG% between B[a]PDE-treated DNA vs control was statistically significant (Fisher’s exact test)
(See, also legends for Fig. 3 and 4). M= Size marker.
doi:10.1371/journal.pone.0010594.g004
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detection of B[a]PDE-DNA adducts [52]. Briefly, heat-denatured
genomic DNA from B[a]PDE-treated cells vs control was dot-
blotted onto a nitrocellulose membrane using the Bio-Dot
Microfiltration Apparatus (Bio-Rad Laboratories, Life Science
Group, Hercules, CA). The membrane was laid over an absorbent
paper pre-soaked with 0.4 N NaOH for 20 minutes at room
temperature. Subsequently, the membrane was blocked by
incubating in phosphate buffered saline plus 0.2% Tween 20
(PBS-T) containing 5% non-fat milk (NFM) at 4uC overnight.
After multiple washes with PBS-T, the membrane was incubated
with BP1-Ab antibody (diluted 1:20,000 in PBS-T plus NFM) for
2 hours at room temperature. The membrane was washed
thoroughly with PBS-T and further incubated with an anti-rabbit
horseradish peroxidase conjugated immunoglobulin (eBioscience,
Inc., San Diego, CA) for 1 hour at room temperature (1:5,000
dilution in PBS-T plus NFM). To reveal peroxidase activity, the
membrane was stained with the Enhanced Chemiluminescence
Detection System (Amersham Biosciences GE Health Care UK
limited, Little Chalfont Buckinghamshire, England) according to
the manufacturer’s instructions. The stained membrane was
exposed to x-ray film, and the relative intensity of luminescence
was determined using the Bio-Rad Imaging Equipment applying
Quantity One image analyzer (Bio-Rad Laboratories).
MIRA-assisted microarray analysis
To catalogue DNA methylation profile in chromosomal regions
of significance in lung cancer, we performed MIRA-assisted
microarray analysis [28] on B[a]PDE-treated normal human
fibroblasts. We used our recently published protocol with some
modifications [30]. Briefly, genomic DNA of B[a]PDE-treated
cells vs control (30 mg each) was fragmented by sonication in a
Branson Sonifier (Model 350, Duty Cycle: 40%, Output: 4) for five
pulses of five seconds each, and one-minute interval among pulses.
The average size of the fragments, determined by electrophoresis
on 1.5% agarose gel, was between 500 to 800 bp. Purified GST-
tagged MBD2b and His-tagged MBD3L1 proteins (60 mg each)
were pre-incubated with a solution containing 10 mM Tris-HCl,
Figure 5. Locus/gene-specific verification of DNA methylation profiles in B[a]PDE-treated cells vs control by COBRA and bisulfite
genomic sequencing. The lack of ‘hypomethylation’ in the specified targets was confirmed by the COBRA [32] and genomic sequencing [33]
methods; none of the differences in
mCG% between B[a]PDE-treated DNA vs control was statistically significant (Fisher’s exact test) (See, also legends
for Figs. 3–5).
doi:10.1371/journal.pone.0010594.g005
DNA Methylation & Cancer
PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e10594pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 3 mM MgCl2,
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(dcm-) bacterial DNA (500 ng) for 20 minutes at 4uCo na
rocking platform. The fragmented DNA was then added to the
pre-incubated mix, and binding of the MBD2b/MBD3L1
complex to methylated CpGs was achieved after an overnight
incubation, as described above. The resultant was mixed with pre-
washed MagneGST glutathione particles (Promega, Madison,
WI), and purified by magnetic capturing according to the
manufacturer’s instructions. The enriched MBD2b/MBD3L-
bound methylated CpG fraction was further processed using the
QIAquick PCR purification kit (Qiagen) to elute the methylated
CpG fraction therein.
Subsequently, methylated CpG-enriched DNA fragments (1 mg)
from B[a]PDE-treated cells vs respective DMSO-treated control or
input DNA (non-enriched control) were labeled with Cy5-dCTP
and Cy3-dCTP (Amersham Biosciences, GE Healthcare UK
limited), respectively, using a BioPrime Array CGH Genomic
Labeling kit (Invitrogen Corp. Carlsbad, CA) (see, Fig. S1 for
detailed information on labeling & hybridization scheme).
Following a purification step, the samples were mixed and
hybridized to NimbleGen tiling arrays (HG18, Set 19, Catalog
# C4524-19-01) according to the NimbleGen’s ChIP-on-chip
protocol (Roche NimbleGen, Inc., Madison, WI). This set of
microarrays covers regions of the long arm of chromosome 7, and
the entire short arm and part of the long arm of chromosome 8,
which contains gene-rich regions of very frequent allele loss in lung
tumors [34]. After hybridization, washing and processing, the
microarray slides were scanned using an Agilent Scanner (Agilent
Technologies Inc., Santa Clara, CA), and images were quantified
by NimbleScan v2.5 (Roche NimbleGen, Inc.). A schematic
representation of our MIRA-assisted microarray approach is
shown in Figure S1. All microarray data are MIAME compliant.
The raw microarray data have been deposited in the Gene
Expression Omnibus repository, which is a MIAME compliant
database, as detailed on the MGED Society website http://www.
mged.org/Workgroups/MIAME/miame.html. The accession nu-
mber for our deposited data is GSE21532.
Microarray data processing and analysis
(I) Identification and annotation of methylated
regions. Preprocessing of raw data and statistical analysis
were performed as described previously with some modifications
[30]. Briefly, Log2 ratios between MIRA-enriched and Input
DNA samples were generated using NimbleScan software (Roche
NimbleGen, Inc.). Probes were selected as positive if their log2
ratios were above 1 (2-fold enriched). For our analysis, we defined
a methylated region of interest (methylation peak) as a region with
at least 4 positive probes covering a minimum length of 350 bp
allowing one gap. Identified methylation peaks were mapped
relative to known transcripts defined in the UCSC genome
browser HG18 RefSeq database (http://hgdownload.cse.ucsc.
edu/goldenPath/hg18/database/). Methylation peaks falling into
1000 bp relative to transcription start sites were defined as ‘‘59-end
peaks’’; methylation peaks falling within 1000 bp of RefSeq
transcript end sites were defined as ‘‘39-end peaks’’, and those
falling within gene bodies (from 1000 bp downstream of
transcription start to 1000 bp upstream of transcript end) were
defined as ‘‘intragenic’’ peaks. Methylation peaks that are not close
to any known transcripts were defined as ‘‘intergenic.’’
(II) Identification of hyper- and hypo-methylated regions
in B[a]PDE treated samples. Hyper- and hypo-methylated
regions in B[a]PDE treated samples were identified by combining
data from all three array designs, including (I) MIRA-enriched
B[a]PDE-treated DNA vs MIRA-enriched DMSO-treated DNA,
(II) MIRA-enriched B[a]PDE-treated DNA vs Input non-enriched
B[a]PDE-treated DNA, and (III) MIRA-enriched DMSO-treated
DNA vs Input non-enriched DMSO-treated DNA. First,
methylation peaks in B[a]PDE treated samples were identified as
described above using data on the array comparing MIRA-
enriched B[a]PDE-treated DNA and Input non-enriched
B[a]PDE-treated DNA and served as the potential candidates of
hyper-methylated regions, which are regions only methylated in
B[a]PDE-treated samples but not in DMSO-treated samples. The
hyper-methylated regions were selected if they satisfied both of the
following criteria: 1) the difference between the average log2 ratios
of probes within these regions in B[a]PDE treated sample (MIRA-
enriched B[a]PDE-treated DNA vs Input non-enriched B[a]PDE-
treated DNA) and the average log2 ratios of probes in untreated
sample (MIRA-enriched DMSO-treated DNA vs Input non-
enriched DMSO-treated DNA) is more than 1 (2-fold); 2) the
average log2 ratios of probes on array comparing MIRA-enriched
B[a]PDE-treated DNA and MIRA-enriched DMSO-treated DNA
were above 1 (2-fold higher comparing MIRA-enriched B[a]PDE-
treated DNA vs MIRA-enriched DMSO-treated DNA). Similar
analysis approach was used to identify hypo-methylated regions,
except that the methylated regions in untreated sample were used
as the starting point to look for difference and signal in MIRA-
enriched B[a]PDE-treated DNA is more than 2-fold lower than
that in MIRA-enriched DMSO-treated DNA.
COBRA and bisulfite genomic sequencing
To verify the data obtained by MIRA-assisted microarray
analysis, we used both the COBRA [32], and bisulfite genomic
sequencing techniques [33] to confirm the methylation status of
individual target loci/genes identified by the above analysis in
B[a]PDE-treated human fibroblasts. Briefly, total genomic DNA
(1 mg) from B[a]PDE-treated cells vs control was subjected to
sodium bisulfite treatment using the Qiagen EpiTect kit according
to the manufacturer’s instructions (Qiagen). The purified bisulfite-
treated DNA was then analyzed by standard COBRA assay [32].
The primer sequences used for PCR amplification of all analyzed
targets are available upon request. HeLa DNA was methylated in
vitro with M. SssI CpG methyltransferase (New England Biolabs,
Ipswich, MA), and served as positive control. For genomic
sequencing, the PCR products obtained after bisulfite conversion
of genomic DNA were cloned into the TOPO-TA cloning vector
(Invitrogen Inc.) according to the manufacturer’s instructions.
Randomly selected clones from B[a]PDE-treated DNA vs control
were sequenced using an ABI-3730 DNA Sequencer (ABI Prism,
PE Applied BioSystems, Foster City, CA).
Supporting Information
Figure S1 A schematic representation of MIRA-assisted micro-
array approach. Modification of DNA with B[a]PDE is shown by
chemical structures bound to the DNA fragments. Methylated and
unmethylated CpGs are indicated as black and white lollipops,
respectively.
Found at: doi:10.1371/journal.pone.0010594.s001 (0.12 MB
PDF)
Figure S2 Quantification of B[a]PDE-DNA adducts by im-
muno-dot-blot assay. Normal human fibroblasts were chronically
treated in vitro with increasing concentrations of B[a]PDE vs
control solvent (DMSO). Immediately after the end of last
treatment, the cells were harvested and genomic DNA was
subjected to immuno-dot-blot assay, as described in the text.
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PDF)
Figure S3 Comparison of DNA methylation profiles between
B[a]PDE-treated cells and control by MIRA-assisted microarray
analysis. Genomic DNA of normal human fibroblasts chronically
treated with B[a]PDE vs control solvent (DMSO) was subjected to
MIRA-assisted microarray analysis, as described in the text.
Representative methylation array profiles from different chromo-
somal regions are shown with corresponding genomic coordinates
(indicated on the top). MIRA-T/MIRA-UT’=MIRA-enriched
B[a]PDE-treated DNA vs MIRA-enriched DMSO-treated DNA,
’MIRA-T/Input’=MIRA-enriched B[a]PDE-treated DNA vs
Input non-enriched B[a]PDE-treated DNA, and ’MIRA-UT/
Input’=MIRA-enriched DMSO-treated DNA vs Input non-
enriched DMSO-treated DNA.
Found at: doi:10.1371/journal.pone.0010594.s003 (0.06 MB
PDF)
Figure S4 Affinity of the MBD2b/MBD3L1 complex for
methylated CpGs in the presence and absence of B[a]PDE-DNA
adducts determined by gel mobility shift assay. A 55-mer
oligonucleotide, containing 1-10 symmetrically methylated CpG
dinucleotides, was treated with increasing concentrations of
B[a]PDE, and subsequently subjected to electromobility gel shift
assay, as described earlier (Rauch et al., 2006). Invariable
formation of the MBD2b/MBD3L1 complex in the presence
and absence of B[a]PDE-DNA adducts is indicated by an arrow.
MBD2-Ab=Negative control, co-incubated with polyclonal
antibody raised specifically against MBD2b protein. Representa-
tive result from the oligonucleotide with 10 methylated CpGs is
shown.
Found at: doi:10.1371/journal.pone.0010594.s004 (0.23 MB
PDF)
Figure S5 Conceptual framework for the methylation detection
assay in repetitive DNA elements. The assay is an adaptation of a
published procedure (Yang et al., 2004), which involves primer
amplification of the consensus sequences from the repetitive DNA
elements followed by appropriate restriction digestion or direct
sequencing (see, text for detailed information on methodology).
Adopted from Ref. (Yang et al., 2004).
Found at: doi:10.1371/journal.pone.0010594.s005 (0.03 MB
PDF)
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